Clinacin 75 mg Tablets for Dogs

Authorised

- Clindamycin hydrochloride

Product identification

Medicine name:
Clinacin 75 mg Tablets for Dogs

Active substance:
Clindamycin hydrochloride

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Clindamycin hydrochloride
81.42 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ01FF01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Germany

Package description:
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 10 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 16 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 20 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 30 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 50 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 80 tablets.
White high density polyethylene bottle with child resistant tamper evidentpolypropylene closure containing 100 tablets.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Well-established use application (Article 13a of Directive No 2001/82/EC)

Marketing authorisation holder:
Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:
12/11/2001

Manufacturing sites for batch release:
Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:
Federal Office Of Consumer Protection And Food Safety

Authorisation number:
400531.01.00

Date of authorisation status change:
3/09/2009

Reference member state:
Ireland

Procedure number:
IE/V/0112/001

Concerned member states:
Denmark Finland France Germany Greece Portugal Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.